Literature DB >> 7982887

Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity.

S Matsubara1, M Take, C Pedraza, T Muramatsu.   

Abstract

MK is a gene that is activated by retinoic acid in embryonal carcinoma (EC) cells and is expressed temporarily during the mid-gestation period of mouse embryogenesis. Midkine, the product of the gene is a novel heparin-binding growth/differentiation factor with neurite outgrowth and neurotrophic activities. The regulatory DNA element in the retinoic acid-induced expression of the MK gene has been investigated. The 1.9 kb 5'-flanking region of the MK gene can mediate retinoic acid-responsive gene expression in F9 and HM-1 EC cells. Analysis of this region by deletion mutagenesis in F9 EC cells shows that there is a retinoic acid-responsive enhancer (designated as REM1) around 900 bp upstream from the transcription start site. This enhancer is composed of two sequence elements, which are located between -1006 and -895 and between -901 and -794. The core element of the upstream region (-971 to -955), whose deletion abolished the retinoic acid responsiveness, contained a sequence highly homologous to a binding site for retinoic acid receptors. Binding of a retinoic acid receptor heterodimer to this core element was verified by gel shift assay. Thus, retinoic acid and the receptor complex can directly induce the expression of a growth/differentiation factor gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982887     DOI: 10.1093/oxfordjournals.jbchem.a124462

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  12 in total

Review 1.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

Review 3.  Midkine in nephrogenesis, hypertension and kidney diseases.

Authors:  Waichi Sato; Yuka Sato
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 4.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

Review 5.  Midkine in inflammation.

Authors:  Ludwig T Weckbach; Takashi Muramatsu; Barbara Walzog
Journal:  ScientificWorldJournal       Date:  2011-12-27

Review 6.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  Overexpression of midkine in pancreatic duct adenocarcinomas induced by N-Nitrosobis(2-oxopropyl)amine in hamsters and their cell lines.

Authors:  M Tsutsumi; K Kadomatsu; T Tsujiuchi; H Sakitani; S Ikematsu; T Kubozoe; M Yoshimoto; T Muramatsu; S Sakuma; Y Konishi
Journal:  Jpn J Cancer Res       Date:  2000-10

8.  Midkine (MK), a heparin-binding growth/differentiation factor, is regulated by retinoic acid and epithelial-mesenchymal interactions in the developing mouse tooth, and affects cell proliferation and morphogenesis.

Authors:  T A Mitsiadis; T Muramatsu; H Muramatsu; I Thesleff
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

9.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

10.  Midkine and NANOG Have Similar Immunohistochemical Expression Patterns and Contribute Equally to an Adverse Prognosis of Oral Squamous Cell Carcinoma.

Authors:  Hyun-Min Kim; Young-Hoon Kang; June-Ho Byun; Si-Jung Jang; Gyu-Jin Rho; Jong-Sil Lee; Bong-Wook Park
Journal:  Int J Mol Sci       Date:  2017-11-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.